Wave Life Sciences (WVE) Income from Continuing Operations (2014 - 2026)
Wave Life Sciences (WVE) posted Income from Continuing Operations of 26087000.0 for Q1 2026, up 50.94% on a QoQ basis from 53179000.0 in Q4 2025, and up 44.35% year-over-year from 18071885.0 in Q1 2025.
Wave Life Sciences (WVE) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Wave Life Sciences' Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 26087000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 44.35% year-over-year to 26087000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 183587000.0 (down 63.44% YoY) and the FY2025 annual result came in at 204378000.0, down 110.68% from the prior year.
- Income from Continuing Operations was 26087000.0 for Q1 2026 at Wave Life Sciences, up from 53179000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 29253000.0 in Q4 2024 and bottomed at 61780000.0 in Q3 2024.
- A 5-year average of 32166588.24 and a median of 37814000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 279.7% in 2024, while the deepest fall reached 951.9% in 2024.
- Wave Life Sciences' Income from Continuing Operations stood at 43709000.0 in 2022, then surged by 62.76% to 16279000.0 in 2023, then jumped by 279.7% to 29253000.0 in 2024, then plunged by 281.79% to 53179000.0 in 2025, then surged by 50.94% to 26087000.0 in 2026.
- Business Quant data shows WVE's Income from Continuing Operations at 26087000.0 in Q1 2026, 53179000.0 in Q4 2025, and 53852000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Wave Life Sciences | 1.16 Bn | 612.38 Mn | - | -26.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.09 Mn |
| Dec 31, 2025 | -53.18 Mn |
| Sep 30, 2025 | -53.85 Mn |
| Jun 30, 2025 | -50.47 Mn |
| Mar 31, 2025 | -46.88 Mn |
| Dec 31, 2024 | 29.25 Mn |
| Sep 30, 2024 | -61.78 Mn |
| Jun 30, 2024 | -32.92 Mn |
| Mar 31, 2024 | -31.56 Mn |
| Dec 31, 2023 | -16.28 Mn |
| Sep 30, 2023 | 7.25 Mn |
| Jun 30, 2023 | -21.10 Mn |
| Mar 31, 2023 | -27.41 Mn |
| Dec 31, 2022 | -43.71 Mn |
| Sep 30, 2022 | -39.00 Mn |
| Jun 30, 2022 | -41.30 Mn |
| Mar 31, 2022 | -37.81 Mn |
| Dec 31, 2021 | -34.79 Mn |
| Sep 30, 2021 | -6.23 Mn |
| Jun 30, 2021 | -38.77 Mn |